<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35314880</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-086X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>45</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cardiovascular and interventional radiology</Title>
          <ISOAbbreviation>Cardiovasc Intervent Radiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Drug-Eluting Balloon for Below the Knee Angioplasty: Five-Year Outcome of the DEBATE-BTK Randomized Clinical Trial.</ArticleTitle>
        <Pagination>
          <StartPage>761</StartPage>
          <EndPage>769</EndPage>
          <MedlinePgn>761-769</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00270-022-03104-3</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The aim of this study is to evaluate the 5-year clinical outcome of the DEBATE-BTK (Drug-eluting balloon for below-the-knee angioplasty evaluation) trial.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">The DEBATE-BTK was a single-center, randomized trial that enrolled 132 diabetic patients with critical limb ischemia. Subjects were randomized 1:1 to DCB or plain old balloon angioplasty (POBA). Major clinical endpoints were, freedom from all-cause death, freedom from clinically driven target lesion revascularization (CDTLR) and the occurrence of major amputation. Additional analysis were conducted to assess overall survival in patients treated with DCB compared to those treated with only POBA in the entire 5-years period and to test the correlation between paclitaxel dose exposure (in terciles) and overall survival.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Freedom from all-cause death at 5 years was 63.1% (41/65) in DCB vs. 53.7%(35/67) POBA patients (p = 0.4). Freedom from CDTLR was 82% in DCB and 63% in POBA patients (p = 0.002) at 1 year and 63 versus 54% at 5 years respectively P = 0.07. One patient in DCB and 2 patients in POBA underwent a major amputation of the target limb. During the 5-year follow-up, 24 patients originally randomized to POBA received DCB treatment for additional limb revascularization. According to DCB treatment in all the 5 years period, overall survival was 66.3.% (30/89) in DCB versus 40%(26/43) in POBA patients, p = 0.003.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Overall survival at 5-year was similar in DCB treated patients compared to POBA. Moreover, survival was higher in patients that received DCB angioplasty at any time of the 5 years period.</AbstractText>
          <AbstractText Label="LEVEL OF EVIDENCE" NlmCategory="METHODS">Level 1b, Individual inception cohort study with &gt; 80% follow-up.</AbstractText>
          <CopyrightInformation>© 2022. Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liistro</LastName>
            <ForeName>Francesco</ForeName>
            <Initials>F</Initials>
            <Identifier Source="ORCID">0000-0002-3668-4059</Identifier>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Department, San Donato Hospital, via Pietro Nenni 20, 52100, Arezzo, Italy. francescoliistro@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reccia</LastName>
            <ForeName>Matteo Rocco</ForeName>
            <Initials>MR</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Department, San Donato Hospital, via Pietro Nenni 20, 52100, Arezzo, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Angioli</LastName>
            <ForeName>Paolo</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Department, San Donato Hospital, via Pietro Nenni 20, 52100, Arezzo, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ducci</LastName>
            <ForeName>Kenneth</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Department, San Donato Hospital, via Pietro Nenni 20, 52100, Arezzo, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ventoruzzo</LastName>
            <ForeName>Giorgio</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Department, San Donato Hospital, via Pietro Nenni 20, 52100, Arezzo, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Falsini</LastName>
            <ForeName>Giovanni</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Department, San Donato Hospital, via Pietro Nenni 20, 52100, Arezzo, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Scatena</LastName>
            <ForeName>Alessia</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Department, San Donato Hospital, via Pietro Nenni 20, 52100, Arezzo, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pieroni</LastName>
            <ForeName>Maurizio</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Department, San Donato Hospital, via Pietro Nenni 20, 52100, Arezzo, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bolognese</LastName>
            <ForeName>Leonardo</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Department, San Donato Hospital, via Pietro Nenni 20, 52100, Arezzo, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cardiovasc Intervent Radiol</MedlineTA>
        <NlmUniqueID>8003538</NlmUniqueID>
        <ISSNLinking>0174-1551</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020099">Coated Materials, Biocompatible</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>P88XT4IS4D</RegistryNumber>
          <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000800" MajorTopicYN="Y">Angioplasty, Balloon</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020099" MajorTopicYN="N">Coated Materials, Biocompatible</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054855" MajorTopicYN="Y">Drug-Eluting Stents</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005263" MajorTopicYN="N">Femoral Artery</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058729" MajorTopicYN="Y">Peripheral Arterial Disease</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011150" MajorTopicYN="N">Popliteal Artery</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>5</Hour>
          <Minute>37</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35314880</ArticleId>
        <ArticleId IdType="doi">10.1007/s00270-022-03104-3</ArticleId>
        <ArticleId IdType="pii">10.1007/s00270-022-03104-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Agnelli G, Belch JJF, Baumgartner I, Giovas P, Hoffmann U. Morbidity and mortality associated with atherosclerotic peripheral artery disease: a systematic review. Atherosclerosis. 2020;293:94–100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.atherosclerosis.2019.09.012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aboyans V, Ricco JB, Bartelink ML, Bjorck M, Brodmann M, Cohner T, Collet JP, Czerny M, De Carlo M, Debus S, Espinola-Klein C, Kahan T, Kownator S, Mazzolai L, Naylor R, Roffi M, Rother J, Sprynger M, Tendera M, Tepe G, Venermo M. Vlachopoulos C and desormais I [2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the european society for vascular surgery (ESVS)]. Kardiol Pol. 2017;75:1065–160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5603/KP.2017.0216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liistro F, Porto I, Angioli P, Grotti S, Ricci L, Ducci K, Falsini G, Ventoruzzo G, Turini F, Bellandi G. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK) a randomized trial in diabetic patients with critical limb ischemia. Circulation. 2013;128:615–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.001811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt A, Ulrich M, Winkler B, Klaeffling C, Bausback Y, Braunlich S, Botsios S, Kruse HJ, Varcoe RL, Kum S, Scheinert D. Angiographic patency and clinical outcome after balloon-angioplasty for extensive infrapopliteal arterial disease. Catheter Cardiovasc Interv. 2010;76:1047–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ccd.22658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kudo T, Chandra FA, Ahn SS. The effectiveness of percutaneous transluminal angioplasty for the treatment of critical limb ischemia: a 10-year experience. J Vasc Surg. 2005;41:423–35 (discussion 435).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jvs.2004.11.041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steiner S, Willfort-Ehringer A, Sievert H, Geist V, Lichtenberg M, Del Giudice C, Sauguet A, Diaz-Cartelle J, Marx C, Strobel A, Schult I, Scheinert D, Investigators RS. 12-month results from the first-in-human randomized study of the ranger paclitaxel-coated balloon for femoropopliteal treatment. JACC Cardiovasc Interv. 2018;11:934–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcin.2018.01.276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schneider PA, Laird JR, Tepe G, Brodmann M, Zeller T, Scheinert D, Metzger C, Micari A, Sachar R, Jaff MR, Wang H, Hasenbank MS, Krishnan P, Investigators IPST. Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN PACT SFA randomized trial. Circ Cardiovasc Interv. 2018;11:e005891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCINTERVENTIONS.117.005891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krishnan P, Faries P, Niazi K, Jain A, Sachar R, Bachinsky WB, Cardenas J, Werner M, Brodmann M, Mustapha JA, Mena-Hurtado C, Jaff MR, Holden AH, Lyden SP. Stellarex drug-coated balloon for treatment of femoropopliteal disease: twelve-month outcomes from the randomized ILLUMENATE pivotal and pharmacokinetic studies. Circulation. 2017;136:1102–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.117.028893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klumb C, Lehmann T, Aschenbach R, Eckardt N, Teichgraber U. Benefit and risk from paclitaxel-coated balloon angioplasty for the treatment of femoropopliteal artery disease: a systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine. 2019;16:42–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eclinm.2019.09.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeller T, Baumgartner I, Scheinert D, Brodmann M, Bosiers M, Micari A, Peeters P, Vermassen F, Landini M, Snead DB, Kent KC, Rocha-Singh KJ, Investigators IPDT. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol. 2014;64:1568–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2014.06.1198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mustapha JA, Brodmann M, Geraghty PJ, Saab F, Settlage RA, Jaff MR, Lutonix BTKSI. Drug-coated vs uncoated percutaneous transluminal angioplasty in infrapopliteal arteries: six-month results of the lutonix BTK Trial. J Invasive Cardiol. 2019;31:205–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31368893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/JAHA.118.011245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schneider PA, Laird JR, Doros G, Gao Q, Ansel G, Brodmann M, Micari A, Shishehbor MH, Tepe G, Zeller T. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. J Am Coll Cardiol. 2019;73:2550–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2019.01.013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Secemsky EA, Kundi H, Weinberg I, Jaff MR, Krawisz A, Parikh SA, Beckman JA, Mustapha J, Rosenfield K, Yeh RW. Association of survival with femoropopliteal artery revascularization with drug-coated devices. JAMA Cardiol. 2019;4:332–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamacardio.2019.0325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freisinger E, Koeppe J, Gerss J, Goerlich D, Malyar NM, Marschall U, Faldum A, Reinecke H. Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis. Eur Heart J. 2019;41:3732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurheartj/ehz698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Paraskevopoulos I, Karnabatidis D. Risk of death and amputation with use of paclitaxel-coated balloons in the infrapopliteal arteries for treatment of critical limb ischemia: a systematic review and meta-analysis of randomized controlled trials. J Vasc Interv Radiol. 2020;31:202–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jvir.2019.11.015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt A, Piorkowski M, Werner M, Ulrich M, Bausback Y, Braunlich S, Ick H, Schuster J, Botsios S, Kruse HJ, Varcoe RL, Scheinert D. First experience with drug-eluting balloons in infrapopliteal arteries: restenosis rate and clinical outcome. J Am Coll Cardiol. 2011;58:1105–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2011.05.034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexandrescu V, Hubermont G, Coessens V, Philips Y, Guillaumie B, Ngongang C, Vincent G, Azdad K, Ledent G, De Marre C, Macoir C. Why a multidisciplinary team may represent a key factor for lowering the inferior limb loss rate in diabetic neuro-ischaemic wounds: application in a departmental institution. Acta Chir Belg. 2009;109:694–700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/00015458.2009.11680519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciavarella A, Silletti A, Mustacchio A, Gargiulo M, Galaverni MC, Stella A, Vannini P. Angiographic evaluation of the anatomic pattern of arterial obstructions in diabetic patients with critical limb ischaemia. Diabete Metab. 1993;19:586–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8026611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baghdasaryan PA, Bae JH, Yu W, Rowe V, Armstrong DG, Shavelle DM, Clavijo LC. “The renal foot” - angiographic pattern of patients with chronic limb threatening ischemia and end-stage renal disease. Cardiovasc Revasc Med. 2020;21:118–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.carrev.2019.09.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graziani L, Silvestro A, Bertone V, Manara E, Andreini R, Sigala A, Mingardi R, De Giglio R. Vascular involvement in diabetic subjects with ischemic foot ulcer: a new morphologic categorization of disease severity. Eur J Vasc Endovasc Surg. 2007;33:453–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejvs.2006.11.022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeller T, Micari A, Scheinert D, Baumgartner I, Bosiers M, Vermassen FEG, Banyai M, Shishehbor MH, Wang H, Brodmann M. The IN.PACT DEEP clinical drug-coated balloon trial: 5-year outcomes. JACC Cardiovasc Interv. 2020;13:431–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcin.2019.10.059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sgueglia GA, Cortese B, Gaspardone A. Late catch-up phenomenon after drug-eluting balloon angioplasty. Int J Cardiol. 2013;168:638–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijcard.2013.04.175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liistro F, Porto I, Grotti S, Angioli P, Brandini R, Ricci L, Ducci K, Falsini G, Tacconi D, Bolognese L. Impact of critical limb ischemia on long term cardiac mortality in diabetic patients undergoing percutaneous coronary revascularization. Eur Heart J. 2012;33:244–5.</Citation>
        </Reference>
        <Reference>
          <Citation>Liistro F, Angioli P, Ventoruzzo G, Ducci K, Reccia MR, Ricci L, Falsini G, Scatena A, Pieroni M, Bolognese L. Randomized controlled trial of Acotec drug-eluting balloon versus plain balloon for below-the-knee angioplasty. JACC Cardiovasc Interv. 2020;13(19):2277–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcin.2020.06.045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liistro F, Weinberg I, Popma AA, Shishehbor MH, Deckers S, Micari A. Paclitaxel-coated balloons versus percutaneous transluminal angioplasty for infrapopliteal chronic total occlusions: the IN.PACT BTK randomised trial. EuroIntervention. 2021;EIJ-D-21–00444.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
